Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study

Ezequiel Córdova, Charlotte-Paige Rolle, Kai Hove, Franco Felizarta, Marc Johnson, Guillermo Cuevas Tascón, Jean-Michel Molina, Joaquin Bravo Urbieta, Laurent Hocqueloux, Sergio Lupo, Carlos M Perez, Björn-Erik Ole Jensen, Celia Jonsson-Oldenbüttel, Francisco Xavier Zamora Vargas, Jason Szabo, Pedro Cahn, Andrea Antinori, Juan Carlos López Bernaldo de Quirós, Antonella Castagna, Monika Bui, Richard Grove, Kehui Wang, Marty St Clair, Riya Moodley, Jacob Radford, Julie Priest, Cassidy A Gutner, Ian Jacob, Avishek Chatterjee, Suryakant Somvanshi, Irina Kolobova, Rekha Trehan, Christopher Polk, Parul Patel, Patricia de los Rios, Paul DiMondi, Lori A Gordon, Kimberley Brown, Harmony P Garges, Bryn Jones · 2026

Read Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study by Ezequiel Córdova, Charlotte-Paige Rolle, Kai Hove, Franco Felizarta, Marc Johnson, Guillermo Cuevas Tascón, Jean-Michel Molina, Joaquin Bravo Urbieta, Laurent Hocqueloux, Sergio Lupo, Carlos M Perez, Björn-Erik Ole Jensen, Celia Jonsson-Oldenbüttel, Francisco Xavier Zamora Vargas, Jason Szabo, Pedro Cahn, Andrea Antinori, Juan Carlos López Bernaldo de Quirós, Antonella Castagna, Monika Bui, Richard Grove, Kehui Wang, Marty St Clair, Riya Moodley, Jacob Radford, Julie Priest, Cassidy A Gutner, Ian Jacob, Avishek Chatterjee, Suryakant Somvanshi, Irina Kolobova, Rekha Trehan, Christopher Polk, Parul Patel, Patricia de los Rios, Paul DiMondi, Lori A Gordon, Kimberley Brown, Harmony P Garges, Bryn Jones (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13619637.txt.

Description

Ezequiel Córdova and colleagues report month eleven and twelve results from the VOLITION study, a 2026 phase 3b trial for people starting HIV treatment. Participants first took a daily two-drug pill combining dolutegravir and lamivudine for up to sixteen weeks. Once the virus was suppressed, each person could choose to switch to long-acting injections of cabotegravir plus rilpivirine every two months, or stay on pills.

Among 171 starters, nearly everyone reached viral suppression, with a median time of about four weeks. Most eligible participants chose the injections, and most of those kept the virus suppressed at month eleven. One person had confirmed treatment failure with drug resistance. Both regimens were well tolerated, and satisfaction rose after the choice point. The authors argue that offering an early switch respects personal needs without losing control of the virus.

Catalog record

CREATOREzequiel Córdova, Charlotte-Paige Rolle, Kai Hove, Franco Felizarta, Marc Johnson, Guillermo Cuevas Tascón, Jean-Michel Molina, Joaquin Bravo Urbieta, Laurent Hocqueloux, Sergio Lupo, Carlos M Perez, Björn-Erik Ole Jensen, Celia Jonsson-Oldenbüttel, Francisco Xavier Zamora Vargas, Jason Szabo, Pedro Cahn, Andrea Antinori, Juan Carlos López Bernaldo de Quirós, Antonella Castagna, Monika Bui, Richard Grove, Kehui Wang, Marty St Clair, Riya Moodley, Jacob Radford, Julie Priest, Cassidy A Gutner, Ian Jacob, Avishek Chatterjee, Suryakant Somvanshi, Irina Kolobova, Rekha Trehan, Christopher Polk, Parul Patel, Patricia de los Rios, Paul DiMondi, Lori A Gordon, Kimberley Brown, Harmony P Garges, Bryn Jones
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13619637

Browse the full library · About the Tower of Babel